Cargando…

Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort

BACKGROUND: Clostridioides difficile infection (CDI) is associated with poor outcomes in patients with inflammatory bowel diseases (IBD). OBJECTIVES: We conducted a nationally representative cohort study to evaluate the impact of recurrent CDI (rCDI)-related hospitalization on longitudinal unplanned...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venkat, Preethi G., Nguyen, Nghia H., Luo, Jiyu, Qian, Alexander S., Khanna, Sahil, Singh, Siddharth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742703/ https://www.ncbi.nlm.nih.gov/pubmed/36518884 http://dx.doi.org/10.1177/17562848221141501

Ejemplares similares

Management of Clostridioides difficile infection in patients with inflammatory bowel disease
por: Khanna, Sahil
Publicado: (2021)

The interplay of Clostridioides difficile infection and inflammatory bowel disease
por: Sehgal, Kanika, et al.
Publicado: (2021)

Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection
por: Voth, Elida, et al.
Publicado: (2021)

The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
por: Seekatz, Anna Maria, et al.
Publicado: (2022)

Management of Clostridioides difficile colitis: insights for the gastroenterologist
por: Saha, Srishti, et al.
Publicado: (2019)

Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients
por: Lam, Angela Y., et al.
Publicado: (2020)

Clostridioides difficile infection: curbing a difficult menace
por: Khanna, Sahil, et al.
Publicado: (2022)

Immune response against Clostridioides difficile and translation to therapy
por: Sehgal, Kanika, et al.
Publicado: (2021)

The interplay of SARS-CoV-2 and Clostridioides difficile infection
por: Khanna, Sahil, et al.
Publicado: (2021)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

Resolution rates in clinical trials for microbiota restoration for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2023)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface
por: Sehgal, Kanika, et al.
Publicado: (2021)

Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection
por: Yu, Si, et al.
Publicado: (2023)

The Current Knowledge on Clostridioides difficile Infection in Patients with Inflammatory Bowel Diseases
por: Boeriu, Alina, et al.
Publicado: (2022)

Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection
por: Saha, Srishti, et al.
Publicado: (2021)

Outcomes in Patients with SARS-CoV-2 and Clostridioides difficile Coinfection
por: Sehgal, Kanika, et al.
Publicado: (2021)

Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2
por: Yadav, Devvrat, et al.
Publicado: (2021)

Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study
por: Saha, Srishti, et al.
Publicado: (2020)

Effect of peripartum Clostridioides difficile infection on pregnancy and neonatal outcomes: an observational study
por: Saha, Srishti, et al.
Publicado: (2023)

Hospitalization With Clostridioides difficile in Pediatric Inflammatory Bowel Disease: a Population-Based Study
por: Kuenzig, M. Ellen, et al.
Publicado: (2022)

Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease
por: Azimirad, Masoumeh, et al.
Publicado: (2020)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease
por: Abdehagh, Mohammad, et al.
Publicado: (2021)

Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease
por: Del Vecchio, Livio Enrico, et al.
Publicado: (2022)

Application of Procalcitonin for the Rapid Diagnosis of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease
por: Xie, Shuhua, et al.
Publicado: (2022)

Melatonin as an Antimicrobial Adjuvant and Anti-Inflammatory for the Management of Recurrent Clostridioides difficile Infection
por: Sutton, S. Scott, et al.
Publicado: (2022)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes
por: Bernard, Rachel, et al.
Publicado: (2022)

Cytotoxic synergism of Clostridioides difficile toxin B with proinflammatory cytokines in subjects with inflammatory bowel diseases
por: Bassotti, Gabrio, et al.
Publicado: (2023)

Risk Factors Associated with Recurrent Clostridioides difficile Infection
por: Negrut, Nicoleta, et al.
Publicado: (2020)

Epidemiology of community-acquired and recurrent Clostridioides difficile infection
por: Fu, Yichun, et al.
Publicado: (2021)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

Sa503 MACHINE LEARNING OUTPERFORMS TRADITIONAL RISK MODEL IN IDENTIFYING HIGH-NEED, HIGH-COST PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN A NATIONALLY REPRESENTATIVE COHORT
por: Nguyen, Nghia H., et al.
Publicado: (2021)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022)

The Prevalence and Risk Factors of Clostridioides difficile Infection in Inflammatory Bowel Disease: 10-Year South Korean Experience Based on the National Database
por: Song, Eun Mi, et al.
Publicado: (2023)

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_akqut6mumvvplnr17i277buuvl